Unknown

Dataset Information

Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2.


ABSTRACT: Immune checkpoint inhibitors (ICIs) and their combination with other therapies such as chemotherapy, fail in most cancer patients. We previously identified the PDZ-LIM domain-containing protein 2 (PDLIM2) as a bona fide tumor suppressor that is repressed in lung cancer to drive cancer and its chemo and immunotherapy resistance, suggesting a new target for lung cancer therapy improvement. In this study, human clinical samples and data were used to investigate PDLIM2 genetic and epigenetic changes in lung cancer. Using an endogenous mouse lung cancer model faithfully recapitulating refractory human lung cancer and a clinically feasible nano-delivery system, we investigated the therapeutic efficacy, action mechanism, and safety of systemically administrated PDLIM2 expression plasmids e

SUBMITTER: Sun F 

PROVIDER: S-EPMC11668523 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature